Core Insights - UroGen Pharma Ltd. has announced improved access to ZUSDURI (mitomycin) for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) due to the implementation of a permanent J Code (J9282) effective January 1, 2026, which is expected to streamline billing and reimbursement processes [1][3][2] Company Overview - UroGen Pharma is a biotech company focused on developing innovative solutions for urothelial and specialty cancers, utilizing proprietary RTGel technology for sustained drug release [6][4] - The company’s first product is approved for low-grade upper tract urothelial cancer, while ZUSDURI is specifically approved for recurrent LG-IR-NMIBC [6][4] Product Information - ZUSDURI is the first and only FDA-approved therapy for adults with recurrent LG-IR-NMIBC, providing a non-surgical chemoablative treatment option [2][4] - The drug is administered directly into the bladder using a urinary catheter in an outpatient setting, allowing for effective tumor treatment without surgery [4][6] Market Context - Approximately 82,000 individuals in the U.S. are diagnosed with NMIBC annually, with around 59,000 experiencing recurrence [5] - The median age of diagnosis for bladder cancer is 73 years, and up to 70% of NMIBC patients may face at least one recurrence, highlighting the need for effective treatment options [5]